Inpatient and Outpatient Orderable

Felbamate Level Build info

Synonyms

  • FELBAMATE LEVEL
  • ANTI-CONVULSANT
  • ANTIEPILEPTIC
  • ANTI-EPILEPTIC
  • AED
  • FELBATOL
  • DRUG
  • ANTICONVULSANT
  • LAB686

Procedure Name

FELBAMATE LEVEL

Procedure Master Number

LAB686

Cerner Name

Procedure ID

64585

Clinical Info

Evaluate toxicity; monitor therapeutic levels

Specimen Sources

 Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous

Specimen Types

 Blood

Container

Red Top Tube

Collection Instructions

Container/Tube: Red Top Tube (Gold not acceptable)
Specimen: 2 mL serum ( 0.6 mL min)

Specimen Volume

2 mL serum ( 0.6 mL min)

Transport Instructions

Refrigerated

Specimen Stability

14 Days Room Temperature, Refrigerated or Frozen

Methodology

Liquid chromatography/tandem mass spectrometry (LC/MS-MS)

Days Performed

TAT: 3- 5 Days

Performing Laboratory

LabCorp

CPT

80167
 
LOINC Code: 6899-9
 
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

PDM

 5900620

Only Orderable at Locations:

 Orderable Everywhere

Results
Component Name Base Name Common Name External Name
FELBAMATE FELBAMATE FELBAMATE Felbamate

Result Interpretation

Therapeutic: 25−104 μg/mL; steady-state trough levels are dose proportional in adults. Multiple daily doses of 1200, 2400, and 3600 mg/day gave trough levels of 25−35, 47−63, and 62−104 μg/mL, respectively. Steady-state peak concentrations are dose proportional in children ages 4 to 12 years over a range of 15, 30, 45 mg/kg/day. The dose proportional peak concentrations were reported as 17, 32, and 49 μg/mL, respectively at two to six hours postdose. Co-administration of carbamazepine, phenytoin, phenobarbital, or primidone can cause a decrease in felbamate plasma concentrations; conversely, valproic acid can increase concentrations.1 In children, a similar effect was found with carbamazepine and phenytoin decreasing levels and an opposite effect with valproic acid.2
1. Bourgeois BF. Pharmacokinetic properties of current antiepileptic drugs: What improvements are needed? Neurology. 2000; 55(Suppl 3):S11-S16. PubMed 11147563
2. Kelley MT, Walson PD, Cox S, Dusci LJ. Population pharmacokinetics of felbamate in children. Ther Drug Monit. 1997 Feb; 19(1):29-36. PubMed 9029743

Forms
edit